Chargement en cours...
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
Although most autoimmune diseases are considered to be CD4 T cell‐ or antibody‐mediated, many respond to CD20‐depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis and off‐label in...
Enregistré dans:
| Publié dans: | Clin Exp Immunol |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7405500/ https://ncbi.nlm.nih.gov/pubmed/32671831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13495 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|